Immatics N.V.(IMTX) - 2024 Q4 - Annual Report

Exhibit 99.1 PRESS RELEASE Immatics Announces Full Year 2024 Financial Results and Business Update Houston, Texas and Tuebingen, Germany, March 27, 2025 – Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a All amounts translated using the exchange rate published by the European Central Bank in effect as of Month 31, 2024 (1 EUR = 1.0389 USD). Immatics Pres ...